TScan Therapeutics to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium
22 juin 2022 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T...
TScan Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
02 juin 2022 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T...
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies
31 mai 2022 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T...
TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell Therapy 25th Annual Meeting
19 mai 2022 07h00 HE
|
TScan Therapeutics, Inc.
Identified lead TCR-T cell therapy candidate, TCR-200-A02, for the treatment of HPV-positive solid tumors, on track for IND submission in 2H22 TCR directed to a novel C*07:02-restricted epitope of...
TScan Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
17 mai 2022 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T...
TScan Therapeutics to Host Virtual KOL Event to Discuss its Solid Tumor Program Strategy and Highlights from the ASGCT 25th Annual Meeting
12 mai 2022 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T...
TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones
09 mai 2022 07h00 HE
|
TScan Therapeutics, Inc.
Preclinical data to be presented at the American Society of Gene & Cell Therapy 25th Annual Meeting; virtual KOL event following the conference Phase 1 umbrella trial for leukemia program...
TScan Therapeutics Announces Upcoming Presentations at the 25th American Society of Gene and Cell Therapy Annual Meeting
02 mai 2022 17h02 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T...
TScan Therapeutics Appoints Leiden Dworak, CPA, MBA, as Vice President, Finance
11 avr. 2022 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered...
TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities
09 mars 2022 07h00 HE
|
TScan Therapeutics, Inc.
Received FDA clearance of IND for TSC-100 for the treatment of hematologic malignancies Phase 1 umbrella trial for liquid tumor program to initiate in H1 2022; preliminary data expected in H2 2022 ...